Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.40
PMD's Cash to Debt is ranked higher than
56% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. PMD: 0.40 )
PMD' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 0.4

Equity to Asset 0.55
PMD's Equity to Asset is ranked higher than
67% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. PMD: 0.55 )
PMD' s 10-Year Equity to Asset Range
Min: 0.55   Max: 0.96
Current: 0.55

0.55
0.96
Interest Coverage No Debt
PMD's Interest Coverage is ranked higher than
88% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. PMD: No Debt )
PMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 6.82
M-Score: -3.01
WACC vs ROIC
7.61%
23.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.06
PMD's Operating margin (%) is ranked higher than
94% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. PMD: 16.06 )
PMD' s 10-Year Operating margin (%) Range
Min: 2.05   Max: 32.29
Current: 16.06

2.05
32.29
Net-margin (%) 10.98
PMD's Net-margin (%) is ranked higher than
92% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. PMD: 10.98 )
PMD' s 10-Year Net-margin (%) Range
Min: 1.48   Max: 20.93
Current: 10.98

1.48
20.93
ROE (%) 25.45
PMD's ROE (%) is ranked higher than
98% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. PMD: 25.45 )
PMD' s 10-Year ROE (%) Range
Min: 3.01   Max: 53.53
Current: 25.45

3.01
53.53
ROA (%) 15.30
PMD's ROA (%) is ranked higher than
98% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. PMD: 15.30 )
PMD' s 10-Year ROA (%) Range
Min: 2.31   Max: 41.36
Current: 15.3

2.31
41.36
ROC (Joel Greenblatt) (%) 32.23
PMD's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. PMD: 32.23 )
PMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.69   Max: 247
Current: 32.23

7.69
247
Revenue Growth (3Y)(%) 9.50
PMD's Revenue Growth (3Y)(%) is ranked higher than
82% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. PMD: 9.50 )
PMD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10   Max: 21.9
Current: 9.5

-10
21.9
EBITDA Growth (3Y)(%) 11.30
PMD's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. PMD: 11.30 )
PMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28   Max: 46.8
Current: 11.3

-28
46.8
EPS Growth (3Y)(%) 12.90
PMD's EPS Growth (3Y)(%) is ranked higher than
87% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. PMD: 12.90 )
PMD' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.7   Max: 138.1
Current: 12.9

-54.7
138.1
» PMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PMD Guru Trades in Q1 2014

Jim Simons 422,100 sh (+4.69%)
Chuck Royce 137,500 sh (unchged)
» More
Q2 2014

PMD Guru Trades in Q2 2014

Jim Simons 439,600 sh (+4.15%)
Chuck Royce 137,500 sh (unchged)
» More
Q3 2014

PMD Guru Trades in Q3 2014

Chuck Royce 137,500 sh (unchged)
Jim Simons 435,200 sh (-1%)
» More
Q4 2014

PMD Guru Trades in Q4 2014

Chuck Royce 137,500 sh (unchged)
Jim Simons 434,900 sh (-0.07%)
» More
» Details

Insider Trades

Latest Guru Trades with PMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.90
PMD's P/E(ttm) is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 25.90 )
PMD' s 10-Year P/E(ttm) Range
Min: 9.01   Max: 39.55
Current: 25.9

9.01
39.55
Forward P/E 18.94
PMD's Forward P/E is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 18.94 )
N/A
PE(NRI) 26.00
PMD's PE(NRI) is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 26.00 )
PMD' s 10-Year PE(NRI) Range
Min: 9.07   Max: 39.68
Current: 26

9.07
39.68
P/B 6.87
PMD's P/B is ranked higher than
64% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. PMD: 6.87 )
PMD' s 10-Year P/B Range
Min: 1.98   Max: 12.3
Current: 6.87

1.98
12.3
P/S 3.04
PMD's P/S is ranked higher than
75% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.67 vs. PMD: 3.04 )
PMD' s 10-Year P/S Range
Min: 0.92   Max: 4.52
Current: 3.04

0.92
4.52
POCF 21.59
PMD's POCF is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 21.59 )
PMD' s 10-Year POCF Range
Min: 6   Max: 35.29
Current: 21.59

6
35.29
EV-to-EBIT 18.37
PMD's EV-to-EBIT is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 18.37 )
PMD' s 10-Year EV-to-EBIT Range
Min: 4.1   Max: 24.3
Current: 18.37

4.1
24.3
PEG 2.52
PMD's PEG is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 2.52 )
PMD' s 10-Year PEG Range
Min: 0.48   Max: 10.07
Current: 2.52

0.48
10.07
Shiller P/E 28.75
PMD's Shiller P/E is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 28.75 )
PMD' s 10-Year Shiller P/E Range
Min: 5.39   Max: 43.79
Current: 28.75

5.39
43.79
Current Ratio 2.44
PMD's Current Ratio is ranked higher than
70% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. PMD: 2.44 )
PMD' s 10-Year Current Ratio Range
Min: 2.4   Max: 18.17
Current: 2.44

2.4
18.17
Quick Ratio 2.44
PMD's Quick Ratio is ranked higher than
74% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. PMD: 2.44 )
PMD' s 10-Year Quick Ratio Range
Min: 2.4   Max: 17.83
Current: 2.44

2.4
17.83
Days Sales Outstanding 50.97
PMD's Days Sales Outstanding is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. PMD: 50.97 )
PMD' s 10-Year Days Sales Outstanding Range
Min: 39.16   Max: 90.06
Current: 50.97

39.16
90.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.66
PMD's Dividend Yield is ranked higher than
92% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.23 vs. PMD: 3.66 )
PMD' s 10-Year Dividend Yield Range
Min: 1.96   Max: 18.28
Current: 3.66

1.96
18.28
Dividend Payout 0.95
PMD's Dividend Payout is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 0.95 )
PMD' s 10-Year Dividend Payout Range
Min: 0.25   Max: 53.33
Current: 0.95

0.25
53.33
Dividend growth (3y) 7.70
PMD's Dividend growth (3y) is ranked higher than
81% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.10 vs. PMD: 7.70 )
PMD' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 7.7

0
26
Yield on cost (5-Year) 4.29
PMD's Yield on cost (5-Year) is ranked higher than
83% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PMD: 4.29 )
PMD' s 10-Year Yield on cost (5-Year) Range
Min: 2.27   Max: 21.19
Current: 4.29

2.27
21.19
Share Buyback Rate -0.60
PMD's Share Buyback Rate is ranked higher than
82% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. PMD: -0.60 )
PMD' s 10-Year Share Buyback Rate Range
Min: 1.9   Max: -1.1
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.87
PMD's Price/Tangible Book is ranked higher than
77% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.13 vs. PMD: 6.87 )
PMD' s 10-Year Price/Tangible Book Range
Min: 3.03   Max: 12.81
Current: 6.87

3.03
12.81
Price/DCF (Projected) 2.89
PMD's Price/DCF (Projected) is ranked higher than
87% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 2.89 )
PMD' s 10-Year Price/DCF (Projected) Range
Min: 0.68   Max: 5.05
Current: 2.89

0.68
5.05
Price/Median PS Value 1.10
PMD's Price/Median PS Value is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. PMD: 1.10 )
PMD' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 5.52
Current: 1.1

0.51
5.52
Price/Peter Lynch Fair Value 2.70
PMD's Price/Peter Lynch Fair Value is ranked higher than
94% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 2.70 )
PMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7   Max: 8.4
Current: 2.7

0.7
8.4
Price/Graham Number 2.82
PMD's Price/Graham Number is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PMD: 2.82 )
PMD' s 10-Year Price/Graham Number Range
Min: 1.27   Max: 14.51
Current: 2.82

1.27
14.51
Earnings Yield (Greenblatt) 5.40
PMD's Earnings Yield (Greenblatt) is ranked higher than
88% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. PMD: 5.40 )
PMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 24.3
Current: 5.4

4.1
24.3
Forward Rate of Return (Yacktman) 11.21
PMD's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.66 vs. PMD: 11.21 )
PMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11.5   Max: 41.2
Current: 11.21

-11.5
41.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Psychemedics Corp is a Delaware corporation organized on September 24, 1986. The Company is a provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company's tests provide quantitative information that can indicate the approximate amount of drug ingested as well as historical data, which can show a pattern of individual drug use over a longer period of time, thereby providing superior detection compared to other types of drug testing. This information is useful to employers for both applicant and employee testing, as well as to physicians, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The Company markets its corporate drug testing services primarily through its own sales force and through distributors. Sales offices are located in cities in the United States in order to facilitate communications with corporate employers. The Company markets its home drug testing service, PDT-90, through the Internet. The Company's customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and internationally. The Company competes directly with commercial laboratories that test for drugs mainly through urinalysis testing. The Company is licensed as a clinical laboratory by the State of California as well as certain other states.
» More Articles for NAS:PMD

Headlines

Articles On GuruFocus.com
Psychemedics: World’s Largest Provider of Hair Testing for Drug Abuse Dec 14 2012 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
7 Highly Profitable Healthcare Dividend Stocks with Great Yields Mar 02 2012 
Guru Stocks Raising Dividends: EPR, CB, PMD, BLK, WSBC Feb 27 2012 
9.31 Feb 12 2012 
sept micro cap stock Sep 19 2011 
18 Low Beta Healthcare Stocks With Best Dividend Yields Jul 02 2011 
Psychemedics Corp: Value in Hair Analysis (PMD) Mar 23 2011 
Psychemedics Corp Reports Operating Results (10-Q) Nov 12 2010 

More From Other Websites
PSYCHEMEDICS CORP Files SEC form 8-K, Financial Statements and Exhibits Feb 27 2015
PSYCHEMEDICS CORP Files SEC form 10-K, Annual Report Feb 27 2015
PSYCHEMEDICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 10 2015
Psychemedics Corporation Announces Record Revenues Feb 10 2015
PSYCHEMEDICS CORP Files SEC form 10-Q, Quarterly Report Oct 31 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
Psychemedics Corporation Announces Record Revenues Oct 30 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Aug 11 2014
PSYCHEMEDICS CORP Financials Aug 06 2014
PSYCHEMEDICS CORP Files SEC form 10-Q, Quarterly Report Jul 30 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2014
Psychemedics Corporation Announces Record Revenues Jul 28 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Jun 16 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... May 23 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 12 2014
PSYCHEMEDICS CORP Files SEC form 10-Q, Quarterly Report May 01 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 29 2014
Psychemedics Corporation Announces Record First Quarter Revenues Apr 29 2014
Psychemedics: Market Is Underestimating The Significance Of Brazil Legislation Apr 26 2014
PSYCHEMEDICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Mar 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK